Correlation Between Entrada Therapeutics and AN2 Therapeutics
Can any of the company-specific risk be diversified away by investing in both Entrada Therapeutics and AN2 Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Entrada Therapeutics and AN2 Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Entrada Therapeutics and AN2 Therapeutics, you can compare the effects of market volatilities on Entrada Therapeutics and AN2 Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Entrada Therapeutics with a short position of AN2 Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Entrada Therapeutics and AN2 Therapeutics.
Diversification Opportunities for Entrada Therapeutics and AN2 Therapeutics
0.29 | Correlation Coefficient |
Modest diversification
The 3 months correlation between Entrada and AN2 is 0.29. Overlapping area represents the amount of risk that can be diversified away by holding Entrada Therapeutics and AN2 Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on AN2 Therapeutics and Entrada Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Entrada Therapeutics are associated (or correlated) with AN2 Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of AN2 Therapeutics has no effect on the direction of Entrada Therapeutics i.e., Entrada Therapeutics and AN2 Therapeutics go up and down completely randomly.
Pair Corralation between Entrada Therapeutics and AN2 Therapeutics
Given the investment horizon of 90 days Entrada Therapeutics is expected to generate 2.37 times less return on investment than AN2 Therapeutics. But when comparing it to its historical volatility, Entrada Therapeutics is 2.21 times less risky than AN2 Therapeutics. It trades about 0.19 of its potential returns per unit of risk. AN2 Therapeutics is currently generating about 0.21 of returns per unit of risk over similar time horizon. If you would invest 107.00 in AN2 Therapeutics on August 26, 2024 and sell it today you would earn a total of 27.00 from holding AN2 Therapeutics or generate 25.23% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Entrada Therapeutics vs. AN2 Therapeutics
Performance |
| Timeline |
| Entrada Therapeutics |
| AN2 Therapeutics |
Entrada Therapeutics and AN2 Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Entrada Therapeutics and AN2 Therapeutics
The main advantage of trading using opposite Entrada Therapeutics and AN2 Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Entrada Therapeutics position performs unexpectedly, AN2 Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AN2 Therapeutics will offset losses from the drop in AN2 Therapeutics' long position.| Entrada Therapeutics vs. Eliem Therapeutics | Entrada Therapeutics vs. HCW Biologics | Entrada Therapeutics vs. Scpharmaceuticals | Entrada Therapeutics vs. Milestone Pharmaceuticals |
| AN2 Therapeutics vs. Eliem Therapeutics | AN2 Therapeutics vs. HCW Biologics | AN2 Therapeutics vs. Scpharmaceuticals | AN2 Therapeutics vs. Milestone Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Complementary Tools
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |